Neurocrine Biosciences | NBIX - Sales Revenues


Neurocrine Biosciences reported $959M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
ALKERMES USD 496.01M 103.1M Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amgen USD 10.1B 1.48B Jun/2026
Biogen USD 2.74B 490M Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Cytokinetics USD 28.6M 9.25M Jun/2026
Enanta Pharmaceuticals USD 16.96M 50.68M Dec/2024
Exelixis USD 628.69M 17.89M Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
Halozyme Therapeutics USD 481M 104M Jun/2026
Incyte USD 1.67B 400M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Prothena USD 51.08M 51.06M Mar/2026
Regeneron Pharmaceuticals USD 4.29B 690M Jun/2026
Repligen USD 204M 10M Jun/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Sarepta Therapeutics USD 401.3M 329.5M Jun/2026
Teva Pharmaceutical Industries USD 12.67B 900M Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Vertex Pharmaceuticals USD 3.33B 340M Jun/2026